FDA Approvals (NDA/BLA action dates by ticker/CIK/drug — authoritative post-event anchor)
bio_fda_approvalsHistorical FDA NDA/BLA approvals — the PIT-authoritative action dates (submission_status_date) per sponsor / brand / active_ingredient. Use to answer 'what has this company been approved for' / 'when did evolocumab clear' / 'how many BLAs in oncology since 2020.' Pairs with catalyst_calendar(pdufa) for the forward calendar and bio_similar_setups for the post-approval comparable cohort.
Coverage (substrate refreshed 2026-06-17): 1,388 NDA/BLA originals since 2015 — 1,363 CDER (openFDA drugsfda pull) + 25 CBER (curated cell/gene/CAR-T cohort). 645+ matched to cik/ticker (CBER match rate 72% — cell/gene sponsors are biotech-pure-play) via super-bio's brand_exact / brand_alias / ingredient_exact / brand_partial matchers with matched_confidence ∈ [0.5, 1.0]. Supplements (sBLA / sNDA) excluded by default — pass originals_only=false to include them.
Inputs (all optional, at least one of ticker_or_cik / drug / modality recommended):
ticker_or_cik— equity ticker or SEC CIK. Filter to one company.drug— ILIKE substring match againstbrand_nameORactive_ingredient(case-insensitive). Either brand (REPATHA) or INN (evolocumab) works.modality— drug-class filter: 'CAR-T' / 'gene_therapy' / 'cell_therapy' / 'mAb' / 'mAb_bispecific' / 'small_molecule' / 'siRNA' / 'antisense_oligo' / 'peptide' / 'protein'. Use this for 'every approved cell/gene therapy' or 'every CAR-T approval' queries — these are the CBER-class rows the modality column was added for. Filter is exact-match on the modality column.since— ISO date floor onsubmission_status_date(default2015-01-01).originals_only— bool, default true. False to include supplements (sNDA / sBLA).min_confidence— float in [0.0, 1.0], default 0.85. Higher = stricter ticker/cik match precision. Important caveat (super-bio note): whenmatched_confidence < 0.9, prefersponsor_namefor filer-correctness — the ticker/cik might be a licensee rather than the original developer. This is especially true for CBER (cell/gene) rows where the approval may have been transferred to a downstream developer.limit— max rows returned (default 50, max 500).
Foreign-private-issuer caveat (super-bio note): 20-F filers in the bio cohort (ARGENX, BNTX, LEGN) aren't in super-bio's universe yet (queued as FUTURE_DIRECTIONS §5 #13). For those, the ticker/cik match either lands on a US licensee (Vyvgart → ZLAB) or cik=NULL. When cik IS NULL but the approval is clearly the foreign filer's drug (recognize via sponsor_name), interpret accordingly.
Response shape: list of {application_number, submission_number, fda_action_date, sponsor_name, brand_name, active_ingredient, modality, source, cik, ticker, matched_method, matched_confidence} rows sorted by submission_status_date DESC. source ∈ {'CDER', 'CBER'} disambiguates row origin. Plus as_of_effective, n_returned, filters_applied.
Live verified spec cases: ticker_or_cik='TVTX' → 3 originals (THIOLA EC 2019-06-28, FILSPARI 2023-02-17, VOYXACT 2025-11-25); drug='evolocumab' → REPATHA AMGN 2015-08-27 (+ 2021 supplement when originals_only=False); ticker_or_cik='REGN', since='2020-01-01' → INMAZEB BLA761169 2020-10-14, EVKEEZA BLA761181 2021-02-11, +6 more; modality='CAR-T' → 7 rows (KYMRIAH 2017-08-30, YESCARTA 2017-10-18, TECARTUS 2020-07-24, BREYANZI 2021-02-05, ABECMA 2021-03-26, CARVYKTI 2022-02-28, AUCATZYL 2024-11-08); modality='gene_therapy' → 12 rows (LUXTURNA 2017-12-19 → BEQVEZ 2024-04-25); modality='cell_therapy' → 6 rows (STRATAGRAFT → RYONCIL — the CAPR-class reference set).
Tool call template
This tool declares no required parameters. Add optional parameters from the input schema as needed.
{
"id": 1,
"jsonrpc": "2.0",
"method": "tools/call",
"params": {
"arguments": {},
"name": "bio_fda_approvals"
}
}Input Schema
| Name | Required | Description | Default |
|---|---|---|---|
| drug | No | Drug name — case-insensitive ILIKE substring against brand_name OR active_ingredient. 'REPATHA' or 'evolocumab' both work. | |
| limit | No | Max rows returned (default 50, max 500). | |
| since | No | ISO date floor on submission_status_date (default 2015-01-01 — the coverage start). | |
| modality | No | Filter by drug class: 'CAR-T' / 'gene_therapy' / 'cell_therapy' / 'mAb' / 'mAb_bispecific' / 'small_molecule' / 'siRNA' / 'antisense_oligo' / 'peptide' / 'protein'. Use for 'every approved cell/gene therapy' queries — the CBER-class rows added 2026-06-17. | |
| ticker_or_cik | No | Equity ticker (e.g. 'AMGN') or SEC CIK integer. Filters approvals to one company. | |
| min_confidence | No | Floor on matched_confidence (default 0.85 for company-scoped queries; auto-lowered to 0.0 when `modality` is set without ticker_or_cik, because the caller wants every approval of that class — CBER rows often have low/zero confidence since the foreign/private cohort isn't fully matched). Lower for broader recall; when < 0.9 prefer sponsor_name over ticker/cik for filer-correctness. | |
| originals_only | No | Default true (submission_number='1' only). False to include supplements (sNDA / sBLA — labeling expansions, new indications, etc.). | |
| exclude_biosimilar | No | Exclude biosimilar/generic approvals (super-bio T030 `biosimilar` flag — FDA -xxxx suffix, disambiguated from suffixed ORIGINATOR biologics by filing sponsor). Default false = every row carries `biosimilar` so you can filter yourself. Set true for ORIGINATOR catalyst events (a company's own new drugs, not its or competitors' biosimilars). Note: cross-company contamination is already removed at the data layer — a company only carries its OWN biosimilars now. |